Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR5088833

—

67a0956b-defa-5a35-82ce-218c69528ee5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.600
  • G2M_CHECKPOINT+0.500
  • MYC_TARGETS_V1+0.400
  • MYC_TARGETS_V2+0.400
  • WNT_BETA_CATENIN_SIGNALING+0.400
  • DNA_REPAIR+0.300
  • MITOTIC_SPINDLE+0.300
  • CHOLESTEROL_HOMEOSTASIS+0.200
  • MTORC1_SIGNALING+0.200
  • MYOGENESIS+0.200

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.500
  • IL6_JAK_STAT3_SIGNALING-0.500
  • INTERFERON_ALPHA_RESPONSE-0.500
  • INFLAMMATORY_RESPONSE-0.400
  • INTERFERON_GAMMA_RESPONSE-0.400
  • COMPLEMENT-0.300
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
  • ANDROGEN_RESPONSE-0.200
  • ANGIOGENESIS-0.200
  • APOPTOSIS-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1C3N-04155
lung-landscapes@6
—cohortSQ20.897
2TCGA-58-8392-01A-11R-2326-07
lung-landscapes@6
—cohortSQ20.888
3TCGA-77-8153-01A-11R-2403-07
lung-landscapes@6
—cohortSQ20.885
4TCGA-56-7823-01B-11R-2247-07
lung-landscapes@6
—cohortSQ20.878
5SRR6013533
lung-landscapes@6
—cohortSQ20.877
6ERR2598212
medullo-epn-umap@date-based
fetalfetal0.873
7TCGA-L3-A524-01A-11R-A262-07
lung-landscapes@6
—cohortSQ20.873
8ERR2598256
medullo-epn-umap@date-based
fetalfetal0.871
9TCGA-58-A46N-01A-11R-A24H-07
lung-landscapes@6
—cohortSQ20.870
10TCGA-77-8128-01A-11R-2247-07
lung-landscapes@6
—cohortSQ20.869

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.600Inavolisib— uncovered
G2M_CHECKPOINT0.500Inavolisib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
MYC_TARGETS_V20.400Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.400Inavolisib— uncovered
DNA_REPAIR0.300Idelalisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.200Remibrutinib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
MYOGENESIS0.200Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
GLYCOLYSIS0.100Inavolisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
HYPOXIA0.100Idelalisib— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
TGF_BETA_SIGNALING0.100Inavolisib— uncovered